A review: Treatment of Alzheimer's disease discovered in repurposed agents

Dementia and Geriatric Cognitive Disorders

Volumn 35, Issue 1-2, 2013, Pages 1-22

  Appleby, Brian S ^a   Nacopoulos, Dimitrios ^a   Milano, Nicholas ^a   Zhong, Kate ^a   Cummings, Jeffrey L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Amyloid; Amyloid peptides; Clinical trials; Dementia; Drug effects; Drug therapy; Pharmacology, clinical; Tau proteins; Tauopathies; Therapeutics

Indexed keywords

ACICLOVIR; AMLODIPINE; AMPHOTERICIN B; AZITHROMYCIN; BEXAROTENE; CLIOQUINOL; DAPSONE; DOXYCYCLINE; ERYTHROMYCIN; EXENDIN 4; FOSCARNET; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INSULIN; ISRADIPINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; MINOCYCLINE; NILVADIPINE; NIMODIPINE; NITRENDIPINE; PACLITAXEL; PENCICLOVIR; PIOGLITAZONE; RIFAMPICIN; ROSIGLITAZONE; THALIDOMIDE; UNINDEXED DRUG; VERAPAMIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIPARKINSON AGENT; ANTIVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; DANTROLENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCAGON LIKE PEPTIDE 1; LITHIUM; MACROLIDE; METHYLENE BLUE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SEROTONIN UPTAKE INHIBITOR; TETRACYCLINE DERIVATIVE; TREHALOSE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BLOOD BRAIN BARRIER; BREAST CANCER; CARDIOTOXICITY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG REPOSITIONING; ERYTHEMA NODOSUM LEPROSUM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KAPOSI SARCOMA; LEPROSY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MEDLINE; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; MYCOBACTERIOSIS; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN INFECTION; TAUOPATHY; ARTICLE;

EID: 84872071676     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000345791     Document Type: Review

References (166)

1. Alzheimer's Association: Alzheimer's Association report: 2012 Alzheimer's disease facts and figures. Alzheimers Dement, 2012.
2. Aisen P, Schneider L, Cummings J: Symptomatic and non-amyloid/tau based pharmacologic treatment for Alzheimer's disease; in Selkoe D, Mandlekow E, Holtzman D (eds): The Biology of Alzheimer's Disease. New York, Cold Spring Harbor Laboratory Press, 2012, p 511.
3. Collins F: Reengineering Translational Science: The Time Is Right. Science Translational Medicine 2011;3:90cm17.
4. Boguski MS, Mandl KD, Sukhatme VP: Drug discovery. Repurposing with a difference. Science 2009;324:1394-1395.
5. Ashburn TT, Thor KB: Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-683. (Pubitemid 39173508)
6. Deftereos SN, Andronis C, Friedla EJ, Persidis A, Persidis A: Dr ug repurposing and adverse event prediction using high-throughput literature analysis. Systems Biol Med 2011;3:323-334.
7. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferrier R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, di Bernardo D: Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA 2010;107:14621.
8. Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, Jarvik JW, Gresham HD, Haynes MK, Hjelle B, Hromas R, Hudson L, Mackenzie DA, Muller CY, Reed JC, Simons PC, Smagley Y, Strouse J, Surviladze Z, Thompson T, Ursu O, Waller A, Wandinger-Ness A, Winter SS, Wu Y, Young SM, Larson RS, Willman C, Sklar LA: Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg 2011;8:61-69.
9. Reaume AG: Drug repurposing through nonhypothesis driven phenotypic screening. Drug Discov Today Ther Strateg 2011; 8:85-88.
10. Schneider P, Tanrikulu Y, Schneider G: Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. Curr Med Chem 2009;16:258-266.
11. Loging W, Rodriguez-Esteban R, Hill J, Freeman T, Miglietta J: Cheminformatic/bioinformatic analysis of large corporate databases: application to drug repurposing. Drug Discov Today Ther Strateg 2011;8:109-116.
12. Toney JH, Fasick JI, Singh S, Beyrer C, Sullivan DJ: Purposeful learning with drug repurposing. Science 2009;325:1339-1340.
13. Henriksen K, Christiansen C, Karsdal MA: Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning. Drug Discov Today 2011;16:967-975.
14. Rang HP: Drug Discovery and Development. Edinburgh, Churchill Livingstone, 2006.
15. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
16. Netzer WJ: Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci USA 2003;100:12444-12449. (Pubitemid 37271579)
17. Fraering PC, Ye W, LaVoie MJ, Ostaszewski BL, Selkoe DJ, Wolfe MS: Gamma-secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem 2005;280:41987-41996. (Pubitemid 43023167)
18. He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, et al: Gamma-secretase activating protein is a therapeutic target for Alzheimers disease. Nature 2010;467:95-98.
19. Cancino GI, Toledo EM, Leal NR, Hernandez DE, Yévenes LF, Inestrosa NC, et al: STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimers beta-amyloid deposits. Brain 2008;131:2425-2442.
20. Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, et al: The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimers disease and related tauopathies. Pharmacol Res 2011;63:341-351.
21. Li G, Faibushevich A, Turunen BJ, Yoon SO, Georg G, Michaelis ML, et al: Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J Neurochem 2003;84:347-362. (Pubitemid 36182276)
22. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VMY, Trojanowski JQ: Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 2005;102:227.
23. Ryu JK, McLarnon JG: Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimers disease brain. Neurobiol Dis 2008;29:254-266.
24. Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, Zinn AE, et al: ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012;335:1503-1506.
25. Payton S, Cahill CM, Randall JD, Gullans SR, Rogers JT: Drug discovery targeted to the Alzheimers APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol. J Mol Neurosci 2003;20:267-275. (Pubitemid 38146981)
26. Tucker S, Ahl M, Cho HH, Bandyopadhyay S, Cuny GD, Bush AI, et al: RNA therapeutics directed to the noncoding regions of APP m RNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Curr Alzheimer Res 2006;3:221-227. (Pubitemid 43988135)
27. Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M: Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 2001;487:404-407. (Pubitemid 32121764)
28. Ono K, Hasegawa K, Naiki H, Yamada M: Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimers beta-amyloid fibrils in vitro. Biochim Biophys Acta 2004;1690:193-202. (Pubitemid 39423614)
29. Diomede L, Cassata G, Fiordaliso F, Salio M, Ami D, Natalello A, et al: Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomers. Neurobiol Dis 2010;40:424-431.
30. Costa R, Speretta E, Crowther DC, Cardoso I: Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease. J Biol Chem 2011;286:41647-41655.
31. Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, et al: A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimers disease. J Am Geriatr Soc 2004;52:381-387. (Pubitemid 38339518)
32. Molloy DW, Standish TI, Zhou Q, Guyatt G, the DARAD Study Group: A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimers disease: the DARAD trial. Int J Geriatr Psychiatry DOI: 10.1002/gps.3846.
33. Choi Y, Kim H-S, Shin KY, Kim E-M, Kim M, Kim H-S, et al: Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimers disease models. Neuropsychopharmacology 2007;32:2393-2404. (Pubitemid 47587688)
34. Hashimoto K: Can minocycline prevent the onset of Alzheimer's disease? Ann Neurol 2011;69:739, author reply 739-740.
35. Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatenzeiler A, et al: Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegen Dis 2010;7:96-98.
36. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH: Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. Faseb J 2009;23:739-750.
37. Parachikova A, Vasilevko V, Cribbs DH, LaFerla FM, Green KN: Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphory-lation. J Alzheimers Dis 2010;21:527-542.
38. Ryu JK, Franciosi S, Sattayaprasert P, Kim SU, McLarnon JG: Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia 2004;48:85-90. (Pubitemid 39390851)
39. Seabrook TJ, Jiang L, Maier M, Lemere CA: Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 2006;53:776-782.
40. Wang Q: Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 2004;24:6049-6056. (Pubitemid 38891095)
41. Wozniak MA, Itzhaki RF: Antiviral agents in Alzheimer's disease: hope for the future? Ther Adv Neurol Disord 2010;3:141-152.
42. Grossi C, Francese S, Casini A, Rosi MC, Luccarini I, Fiorentini A, et al: Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 2009;17:423-440.
43. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685.
44. Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, et al: Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 1996;271:6839-6844.
45. Abuznait AH, Cain C, Ingram D, Burk D, Kaddoumi A: Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease. J Pharm Pharmacol 2011;63:1111-1118.
46. Hartsel SC, Weiland TR: Amphotericin B binds to amyloid fibrils and delays their formation: a therapeutic mechanism? Biochemistry 2003;42:6228-6233. (Pubitemid 36605125)
47. Smith NW, Annunziata O, Dzyuba SV: Amphotericin B interactions with soluble oligomers of amyloid Abeta1-42 peptide. Bioorg Med Chem 2009;17:2366-2370.
48. McGeer PL, Harada N, Kimura H, McGeer EG, Schulzer M: Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dement Geriatr Cogn Disord 1992;3:146-149.
49. Namba Y, Kawatsu K, Izumi S, Ueki A, Ikeda K: Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet 1992;340:978.
50. Kimura T, Goto M: Existence of senile plaques in the brains of elderly leprosy patients. Lancet 1993; 342: 1364. (Pubitemid 23345194)
51. Chui DH, Tabira T, Izumi S, Koya G, Ogata J: Decreased beta-amyloid and increased abnormal tau deposition in the brain of aged patients with leprosy. Am J Pathol 1994;145:771-775.
52. Goto M, Kimura T, Hagio S, Ueda K, Kitajima S, Tokunaga H, et al: Neuropathological analysis of dementia in a Japanese leprosarium. Dementia 1995;6:157-161.
53. Endoh M, Kunishita T, Tabira T: No effect of anti-leprosy drugs in the prevention of Alzheimer's disease and beta-amyloid neurotoxicity. J Neurol Sci 1999;165:28-30. (Pubitemid 29298077)
54. Chen Y, Zhou K, Wang R, Liu Y, Kwak Y-D, Ma T, et al: Antidiabetic drug metformin (Glucophage®) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 2009;106:3907-3912.
55. Gupta A, Bisht B, Dey CS: Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011;60:910-920.
56. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, et al: Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA 2010;107: 21830-21835.
57. De Felice FG, Vieira MNN, Bomfim TR, Decker H, Velasco PT, Lambert MP, et al: Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 2009;106:1971-1976.
58. Toledo EM, Inestrosa NC: Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 2010;15:272-285, 228.
59. Rodriguez-Rivera J, Denner L, Dineley KT: Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav Brain Res 2011;216:255-261.
60. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR: Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006;199:265-273. (Pubitemid 43928978)
61. Escribano L, Simón A-M, Pérez-Mediavilla A, Salazar-Colocho P, Del Río J, Frechilla D: Rosiglita zone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 2009;379:406-410.
62. Escribano L, Simón A-M, Gimeno E, Cuadrado-Tejedor M, López de Maturana R, García-Osta A, et al: Rosi-glitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010;35:1593-1604.
63. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al: Preser ved cognit ion in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosigli-tazone: a preliminary study. Am J Geriatr Psychiatry 2005;13:950-958. (Pubitemid 46638661)
64. Risner ME, Saunders AM, Altman JFB, Ormandy GC, Craft S, Foley IM, et al: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6:246-254. (Pubitemid 44137951)
65. Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, et al: A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis 2010;22:1241-1256.
66. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, et al: Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010;30:131-146.
67. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, et al: Rosiglita zone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res 2011;8:592-606.
68. Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, et al: Complete rescue of cere-brovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 2008;28:9287-9296.
69. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, et al: Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005;128:1442-1453. (Pubitemid 40826196)
70. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T: Efficacy of PPAR-γ a gonist pioglit a zone in mi ld Alzheimer disease. Neurobiol Aging 2011;32:1626-1633.
71. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T: Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 2009;57:177-179.
72. Hanyu H, Sato T, Sakurai H, Iwamoto T: The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease. J Am Geriatr Soc 2010;58:1000-1001.
73. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G: A randomized pilot clinical trial of the safety of pio-glitazone in treatment of patients with Alzheimer disease. Arch Neurol 2011;68:45-50.
74. McClean PL, Gault VA, Harriott P, Hölscher C: Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010;630:158-162.
75. McClean PL, Parthsarathy V, Faivre E, Holscher C: The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011;31:6587-6594.
76. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, et al: Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003;72:603-612. (Pubitemid 36578646)
77. Chen S, Liu A-R, An F-M, Yao W-B, Gao X-D: Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr) DOI: 10.1007/s11357-011-9303-8.
78. Hunter K, Hölscher C: Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012;13:33.
79. Tamaki C, Ohtsuki S, Terasaki T: Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1-40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 2007;72:850-855. (Pubitemid 47481408)
80. Jiang L-H, Zhang Y-N, Wu X-W, Song F-F, Guo D-Y: Effect of insulin on the cognizing function and expression of hippocampal Abeta1-40 of rat with Alzheimer disease. Chin Med J 2008;121:827-831.
81. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al: Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008;13:323-331. (Pubitemid 352039034)
82. Reger MA, Watson GS, Frey WH, Baker LD, Cholerton B, Keeling ML, et al: Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27:451-458. (Pubitemid 43185331)
83. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al: Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilotclinical trial. Arch Neurol 2012;69:29-38.
84. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, et al: Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 1999;56:1135-1140.
85. Shepardson NE, Shankar GM, Selkoe DJ: Cholesterol level and statin use in Alzheimer disease. I. Review of epidemiological and preclinical studies. Arch Neurol 2011;68:1239-1244.
86. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al: Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010;74:956-964.
87. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P: Cochrane review on 'Statins for the treatment of dementia.' Int J Geriatr Psychiatry DOI: 10.1002/gps.3797.
88. Shepardson NE, Shankar GM, Selkoe DJ: Cholesterol level and statin use in Alzheimer disease. II. Review of human trials and recommendations. Arch Neurol 2011;68:1385-1392.
89. Wagner G, Icks A, Abholz H-H, Schröder-Bernhardi D, Rathmann W, Kostev K: Antihypertensive treatment and risk of dementia: a retrospective database study. Int J Clin Pharmacol Ther 2012;50:195-201.
90. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, et al: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-1351. (Pubitemid 28510916)
91. Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, et al: Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res 2004;999:53-61. (Pubitemid 38121450)
92. Paris D, Bachmeier C, Patel N, Quadros A, Volmar C-H, Laporte V, et al: Selective antihypertensive dihydro-pyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med 2011;17:149-162.
93. Hanyu H, Hirao K, Shimizu S, Sato T, Kiuchi A, Iwamoto T: Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int J Geriatr Psychiatry 2007;22:1264-1266. (Pubitemid 350285434)
94. Kennelly S, Abdullah L, Kenny RA, Mathura V, Luis CA, Mouzon B, et al: Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients-an open-label trial. Int J Geriatr Psychiatry 2011;27:415-422.
95. Kennelly SP, Abdullah L, Paris D, Parish J, Mathura V, Mullan M, et al: Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry 2011;26:1038-1045.
96. López-Arrieta JM, Birks J: Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002;3:CD000147.
97. Anekonda TS, Quinn JF, Harris C, Frahler K, Wadsworth TL, Woltjer RL: L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis 2011;41:62-70.
98. Popović M, Caballero-Bleda M, Popović N, Bokonjić D, Dobrić S: Neuroprotective effect of chronic verapamil treatment on cognitive and noncognitive deficits in an experimental Alzheimer's disease in rats. Int J Neurosci 1997;92:79-93.
99. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM: Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 2011;26:699-708.
100. Ferrington L, Miners JS, Palmer LE, Bond SM, Povey JE, Kelly PAT, et al: Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease. Am J Transl Res 2011;3:197.
101. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al: Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007;117:3393-3402. (Pubitemid 350096995)
102. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, et al: Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009;54:1345-1352.
103. 2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 1995;16:187-198.
104. Smith AM, Gibbons HM, Dragunow M: Valproic acid enhances microglial phagocytosis of amyloid-beta(1-42). Neuroscience 2010;169:505-515.
105. Qing H, He G, Ly PTT, Fox CJ, Staufenbiel M, Cai F, et al: Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008;205:2781-2789.
106. Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, et al: Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68:853-861.
107. Hellweg R, Ziegenhorn A, Heuser I, Deuschle M: Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmaco-psychiatry 2008;41:66-71. (Pubitemid 351427525)
108. Chadwick W, Mitchell N, Caroll J, Zhou Y, Park S-S, Wang L, et al: Amitriptyline-mediated cognitive enhancement in aged 3 × Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. PloS One 2011;6:e21660.
109. Jang S-W, Liu X, Chan C-B, Weinshenker D, Hall RA, Xiao G, et al: Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol 2009;16:644-656.
110. Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF: Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci 2010;22:8-18.
111. Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, et al: Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci USA 2011;108:14968-14973.
112. Grote HE, Bull ND, Howard ML, van Dellen A, Blakemore C, Bartlett PF, et al: Cognitive disorders and neuro-genesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 2005;22:2081-2088. (Pubitemid 41579396)
113. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, et al: The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol 2008;210:154-163.
114. Duan W, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, et al: Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol Dis 2008; 30: 312-322.
115. Chow TW, Pollock BG, Milgram NW: Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatr Dis Treat 2007;3:627-636. (Pubitemid 350090293)
116. Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, et al: Prophylactic treatment with parox-etine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3 × TgAD mice. Exp Neurol 2007;205:166-176. (Pubitemid 46617502)
117. Youdim MBH, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, et al: Rasagiline: neurodegen-eration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 2005;79:172-179. (Pubitemid 40116432)
118. Jenner P: Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 2004;63:S13-S22. (Pubitemid 39346707)
119. Youdim MBH: The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuropro-tective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res 2006;3:541-550. (Pubitemid 46066429)
120. Bar Am O, Amit T, Weinreb O, Youdim MBH, Mandel S: Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-bet a protein prec ursor: involvement of MA PK and PKC activation. J Alzheimers Dis 2010;21:361-371.
121. Camins A, Verdaguer E, Junyent F, Yeste-Velasco M, Pelegrí C, Vilaplana J, et al: Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther 2009;15:333-344.
122. Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, et al: Lithium trial in Alzheimer's disease. J Clin Psychiatry 2009;70:922-931.
123. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF: Disease-modifying properties of longterm lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011;198:351-356.
124. Kodama M, Fujioka T: Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004;56:570-580. (Pubitemid 39336404)
125. Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, et al: Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Int J Geriatr Psychiatry 2005;20:1020-1027. (Pubitemid 41723572)
126. Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, et al: Cognitive effects of atypical antipsy-chotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 2011;168:831-839.
127. Chu J, Praticò D: Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model. Am J Pathol 2011;178:1762-1769.
128. In t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al: Nonsteroidal antiinflam-matory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521. (Pubitemid 33144916)
129. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al: Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011;7:402-411.
130. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-216. (Pubitemid 33051236)
131. Zemer D, Livneh A, Langevitz P: Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann Intern Med 1992;116:426.
132. Refolo LM, Sambamurti K, Efthimiopoulos S, Pappolla MA, Robakis NK: Evidence that secretase cleavage of cell surface Alzheimer amyloid precursor occurs after normal endocytic internalization. J Neurosci Res 1995;40:694-706.
133. Aisen PS, Marin DB, Brickman AM, Santoro J, Fusco M: Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:96-101. (Pubitemid 32525448)
134. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, et al: Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002;52:253-256. (Pubitemid 34810613)
135. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al: Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflamm 2010;7:90.
136. Fillit H, Hess G, Hill J, Bonnet P, Toso C: IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009;73:180-185.
137. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al: 18-month study of intravenous immu-noglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30:1728-1736.
138. Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJE: New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J Biol Chem 2002;277:42881-42890. (Pubitemid 35285665)
139. Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, et al: Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann Neurol 2011;69:248-256.
140. Uberti D, Bianchi I, Olivari L, Ferrari-Toninelli G, Canonico P, Memo M: Pramipexole prevents neurotoxicity induced by oligomers of beta-amyloid. Eur J Pharmacol 2007;569:194-196. (Pubitemid 47198246)
141. Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, Kato H, et al: Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. Faseb J 2008;22:703-712. (Pubitemid 351348123)
142. Callaway NL, Riha PD, Bruchey AK, Munshi Z, Gonzalez-Lima F: Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav 2004;77:175-181. (Pubitemid 38076994)
143. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR: Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 1996;93:11213-11218. (Pubitemid 26333144)
144. Taniguchi S, Suzuki N, Masuda M, Hisanaga S-I, Iwatsubo T, Goedert M, et al: Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 2005;280:7614-7623. (Pubitemid 40349654)
145. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, et al: Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 2012;8:609-622.
146. Jinwal UK, Miyata Y, Koren J, Jones JR, Trotter JH, Chang L, et al: Chemical manipulation of Hsp70 ATPase activity regulates tau stability. J Neurosci 2009;29:12079-12088.
147. O'Leary JC, Li Q, Marinec P, Blair LJ, Congdon EE, Johnson AG, et al: Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurode-gener 2010;5:45.
148. Van Bebber F, Paquet D, Hruscha A, Schmid B, Haass C: Methylene blue fails to inhibit tau and polyglu-tamine protein dependent toxicity in zebrafish. Neurobiol Dis 2010;39:265-271.
149. Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, Tone P, et al: Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 2007;46:8850-8860. (Pubitemid 47208418)
150. Medina DX, Caccamo A, Oddo S: Methylene blue reduces Aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 2011;21:140-149.
151. Gura T: Hope in Alzheimer's fight emerges from unexpected places. Nat Med 2008;14:894-894.
152. Mousavi M, Hellström-Lindahl E: Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int 2009;54:237-244.
153. Srivareerat M, Tran TT, Salim S, Aleisa AM, Alkadhi KA: Chronic nicotine restores normal Aβ levels and prevents short-term memory and E-LTP impairment in Aβ rat model of Alzheimer's disease. Neurobiol Aging 2011;32:834-844.
154. Sabbagh MN, Walker DG, Reid RT, Stadnick T, Anand K, Lue L-F: Absence of ef fect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). Neurosci Lett 2008;448:217-220.
155. Deng J, Shen C, Wang Y-J, Zhang M, Li J, Xu Z-Q, et al: Nicotine exacerbates tau phosphorylation and cognitive impairment induced by amyloid-beta 25-35 in rats. Eur J Pharmacol 2010;637:83-88.
156. Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, et al: Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 2012;78:91-101.
157. Reddy AS, Izmitli A, de Pablo JJ: Effect of trehalose on amyloid beta (29-40)-membrane interaction. J Chem Phys 2009;131:085101.
158. Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP: Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem 2000;275:18195-18200. (Pubitemid 30414771)
159. Cheung K-H, Shineman D, Müller M, Cárdenas C, Mei L, Yang J, et al: Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 2008;58:871-883. (Pubitemid 351842747)
160. Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I: Role of presenilins in neuronal calcium homeo-stasis. J Neurosci 2010;30:8566-8580.
161. Mullard A: Protein-protein interaction inhibitors get into the groove. Nat Rev Drug Discov 2012;11:173-175.
162. Smith RB: Repositioned drugs: integrating intellectual property and regulatory strategies. Drug Discov Today Ther Strateg 2011;8:131-137.
163. Sabbagh JJ, Kinney JW, Cummings JL: Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Neurobiol Aging 2013;34:169-183.
164. Glass DJ, Hall N: A brief history of the hypothesis. Cell 2008;134:378-381.
165. Cohen KB, Hunter L: Getting started in text mining. PLoS Comput Biol 2008;4:e20.
166. Rzhetsky A, Seringhaus M, Gerstein MB: Getting started in text mining: part two. PLoS Comput Biol 2009;5:e1000411.